Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8895694 Glucagon-Like Peptide-1 derivatives and their pharmaceutical use

Patent 8895694 was granted and assigned to Novo Nordisk on November, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

8895694

Date of Patent

November 25, 2014

Patent Application Number

12676451

Date Filed

September 5, 2008

Patent Citations Received

‌

US Patent 12090193 Glucagon-like peptide 1 receptor agonists and uses thereof

‌

US Patent 11779633 Glucagon-like peptide 1 receptor agonists and uses thereof

‌

US Patent 11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

‌

US Patent 11891425 Thioamide-modified peptides and uses thereof

‌

US Patent 11759503 Compositions of GLP-1 peptides and preparation thereof

‌

US Patent 11759502 Compositions of GLP-1 peptides and preparation thereof

‌

US Patent 11759501 Compositions of GLP-1 peptides and preparation thereof

Patent Primary Examiner

‌

James H Alstrum-Acevedo

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8895694 Glucagon-Like Peptide-1 derivatives and their pharmaceutical use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API